N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

Sponsor: Pfizer • ClinicalTrials.gov ID: NCT06698796

Registry updated: 2026-08-25
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis \[DM\] or polymyositis \[PM\]). Idiopathic inflammatory myopathies are a group of disorders that show inflammation of the muscles used for movement. There are several types of idiopathic inflammatory myopathies, including DM and PM. DM and PM involve weakness of the muscles closest to the center of the body, such as the muscles of the hips, thighs, upper arms, and neck. People with these forms of idiopathic inflammatory myopathies may find it difficult to climb stairs, get up from a seated position, or lift items above their head. People with DM can also have a skin rash. These disorders negatively impact the quality of life and functioning of patients. In addition to the above, these disorders can affect how the lungs and heart work. This study is seeking participants who took part in a DM and PM study with dazukibart before. Some participants will receive study medicine, and some participants will not receive study medicine and only complete safety follow-up. The study medicine will be given as an intravenous (IV) infusion (directly into the veins). This takes about 1 hour, every 4 weeks, from Day 1 to Week 48 (about 12 months) of the study. This will be followed by a safety follow-up period that lasts about 4 months after the last infusion. Participants who receive study medicine will have about 18 study visits at the site over about 16 months. There will also be participants enrolled in this study who will not receive study medicine. Such participants will only take part in safety follow-up visits as they do not want to or are not eligible to receive dazukibart. These participants will not receive study medicine and will have up to 4 study visits at the site every 4 weeks to complete safety follow-up.

Interventions

  • Dazukibart (Drug)
    anti-interferon beta therapy

Eligibility criteria

Inclusion Criteria: * Participants that completed a qualifying study through Week 52. Exclusion Criteria: * Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation. * Previous administration with an investigational product (drug or vaccine) other than dazukibart in a qualifying study within 30 days (or as determined by the local requirement) or 5 half-lives preceding baseline in this study (whichever is longer). * Current use of any prohibited concomitant medication(s). * Active bacterial, viral, fungal, mycobacterial or other infections. * Ongoing adverse event in a qualifying study or the participant has met safety monitoring criteria in a qualifying study that have not resolved. * Investigator site staff or sponsor employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Conditions

Dermatomyositis Polymyositis

Locations

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale — Glendale, Arizona, United States
  • Arthritis & Rheumatology Research Institute, PLLC — Frisco, Texas, United States
  • Nerve & Muscle Center of Texas — Houston, Texas, United States
  • Rheumatology & Pulmonary Clinic — Beckley, West Virginia, United States
  • IR Medical Center SA - Instituto de Reumatologia — Mendoza, Mendoza Province, Argentina
  • Centro de Investigaciones Médicas Tucuman — SAN M. de Tucuman, Tucumán Province, Argentina
  • Medical Center Artmed — Plovdiv, Bulgaria
  • Anhui Provincial Hospital — Hefei, Anhui, China
  • The Second Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China
  • The Second Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China
  • Renji Hospital Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality, China
  • Renji Hospital Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality, China
  • First Affiliated Hospital of Kunming Medical University — Kunming, Yunnan, China
  • Peking Union Medical College Hospital — Beijing, China
  • Debreceni Egyetem Klinikai Kozpont — Debrecen, Hungary
  • Medanta - The Medicity — Gurugram, Haryana, India
  • CHARM HEALTHCARE PRIVATE LIMITED (Previously Dr Shenoy's Care Private Limited) — Ernākulam, Kerala, India
  • Sheba Medical Center — Ramat Gan, Central District, Israel
  • Institute of Science Tokyo Hospital — Bunkyo-ku, Tokyo, Japan
  • Nippon Medical School Hospital — Bunkyo-ku, Tokyo, Japan
  • Cryptex Investigación Clínica S.A. de C.V. — Cuauhtémoc, Mexico City, Mexico
  • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji — Warsaw, Masovian Voivodeship, Poland
  • Nova Reuma Domyslawska i Rusilowicz Spolka Partnerska Lekarza Reumatologa i Fizjoterapeuty — Bialystok, Podlaskie Voivodeship, Poland
  • Chi Mei Medical Center — Tainan, Taiwan
  • National Taiwan University Hospital — Taipei, Taiwan
  • Hacettepe Universite Hastaneleri — Altindağ, Ankara, Turkey (Türkiye)
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record